MAPK8 and myeloid sarcoma: Further study showed that SP600125, JNK inhibitor, greatly reversed the p-LRP6 level after UII treatment during MS, but LRP6 overexpression did not affect the upregulation of p-JNK induced by UII during MS, although it slightly decreased p-JNK level after MS (Fig. 6G and H).